Testing antibodies in itching after immune therapy
Part of Immune system & allergy, Skin clinical trials.
This study checks blood antibodies (BP180 and BP230) in people who develop long-lasting itching after starting immune therapy for cancer. It may help doctors understand why the itching happens and how it relates to autoimmune skin conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently on immune therapy (pembrolizumab, nivolumab, atezolizumab, or durvalumab), or you finished it within the last 6 months
- Your itching (pruritus) has lasted more than 1 month and started after you began immune therapy
- There was no obvious skin rash or skin disease that explains the itching at the time it began
- If you can become pregnant, you must use effective birth control and have a recent negative pregnancy test
- You must sign an informed consent form and be covered by a social security program
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called TriCalm Hydrogel to see if it helps reduce itching caused by immunotherapy cancer treatment. If you have itching from your immunotherapy, this study might offer relief.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This trial tests an investigational drug called ATTO-1310 to see if it can reduce chronic itching that has no clear cause. It may help people who have tried antihistamines without success.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
This trial tests if dupilumab (Dupixent) can help adults with long-lasting, severe itching from healed burn scars. It is for people whose itching has not improved with standard treatments like antihistamines.
Hear when a new Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.